research The Changing Landscape of Alopecia Areata: The Translational Landscape
New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
Search
for
Sort by
Research
30 / 237 results 
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Gene Expression Signatures and ALADIN Score Correlate with Response of Alopecia Areata Patients to Treatment with JAK Inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Recent Advances in the Genetics of Alopecia Areata
New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Integrative Analysis of Rare Copy Number Variants and Gene Expression Data in Alopecia Areata Implicates an Etiological Role for Autophagy
The research suggests that autophagy-related genes might play a role in causing alopecia areata.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
research Predictive Modeling of Patient Response to JAK/STAT Inhibitors and Dynamic Patient-Matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Promotion of Hair Growth in Alopecia Areata by Topical Treatment of HDAC Inhibitors
HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research Whole Exome Sequencing in Alopecia Areata Identifies Rare Variants in KRT82
Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.
research Gender Difference in Relationship Between Serum Ferritin and 25-Hydroxyvitamin D in Korean Adults
Men and premenopausal women in Korea show different patterns in iron and vitamin D levels, with no clear pattern for postmenopausal women.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research Androgenetic Alopecia and Metabolic Syndrome: Is Alarin a Missing Link?
Higher alarin levels might link hair loss and metabolic syndrome.
research North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations
There is no standardized treatment for hidradenitis suppurativa, and individualized plans are needed.
research First Use of Thymus Transplantation Therapy for FOXN1 Deficiency (Nude/SCID): A Report of 2 Cases
Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.